Mountain Valley MD Holdings Inc. is a biotech company focused on enhancing health solutions for humans, animals, and plants in Canada. While it boasts a strong liquidity position with a current ratio of 15.04 and no debt, its financial health is concerning, highlighted by extremely negative EBITDA and net margins, indicating significant operational challenges. The stock price has seen a positive movement of 7.69%, but the overall market cap of $24.66M suggests limited investor confidence. The disparity between high liquidity and poor profitability raises questions about sustainable growth.
Loading financial metrics...
Company has $997K in cash but burned $810K last quarter. At this burn rate, only 1.2 quarters of runway remain without additional financing.
Revenue fell 87.7% year-over-year from $382K to $47K. The decline has persisted for multiple quarters.
Company posted a loss of $-7.4M over the last year, representing 15759.6% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $3.2M over the last year.
Gross margin expanded by 38.8 percentage points, indicating improved pricing power or cost efficiency.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 15.0x ensures operational stability.
Low debt-to-revenue ratio of 0.0% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q2 (June 30, 2025)